Replies to post #684 on Repro Med Systems Inc (REPR)

[GWMAN]

Well, I am not the REPR expert by any means, but there are at least 3 I can think of:

1. The biggest by far is that we know that REPR requires a second shift to meet the demand from its customers and distributors. The impacts of that second shift on rtevenue will not really be visible until the October report.

2. There is various evidence that REPR is improving its reach to hospitals for at least the Resevac (or however you spell it). This increased focus could show up in July numbers but October more likely, as we have a production limitation problem at the moment.

3. From what little I have read, I really like the new needle set stuff and I think as we move toward second have of the year we may get some interesting additional revenue on that front, but I know nothing about regulatory hoops on that front so my hope for that new product may be 6 months premature as far as revenue goes.